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ARTICLE
An LRP8 Variant Is Associated with Familial and Premature
Coronary Artery Disease and Myocardial Infarction
Gong-Qing Shen, Lin Li, Domenico Girelli, Sara B. Seidelmann, Shaoqi Rao, Chun Fan,
Jeong Euy Park, Quansheng Xi, Jing Li, Ying Hu, Oliviero Olivieri, Kandice Marchant,
John Barnard, Roberto Corrocher, Robert Elston, June Cassano, Susan Henderson, Stanley L. Hazen,
Edward F. Plow, Eric J. Topol,* and Qing K. Wang*
Our previous genomewide linkage scan of 428 nuclear families (GeneQuest) identified a significant genetic susceptibility
locus for premature myocardial infarction (MI) on chromosome 1p34-36. We analyzed candidate genes in the locus with
a population-based association study involving probands with premature coronary artery disease (CAD) and/or MI from
the GeneQuest families (381 cases) and 560 controls without stenosis detectable by coronary angiography. A noncon-
servative substitution, R952Q, in LRP8 was significantly associated with susceptibility to premature CAD and/or MI by
use of both population-based and family-based designs. Three additional white populations were used for follow-up
replication studies: another independent cohort of CAD- and/or MI-affected families (GeneQuest II: 441 individuals from
22 pedigrees), an Italian cohort with familial MI (248 cases) and 308 Italian controls, and a separate Cleveland GeneBank
cohort with sporadic MI (1,231 cases) and 560 controls. The association was significantly replicated in two independent
populations with a family history of CAD and/or MI, the GeneQuest II family-based replication cohort and the Italian
cohort, but not in the population with sporadic disease. The R952Q variant of LRP8 increased activation of p38 mitogen-
activated protein kinase by oxidized low-density lipoprotein. This extensive study, involving multiple independent pop-
ulations, provides the first evidence that genetic variants in LRP8 may contribute to the development of premature and
familial CAD and MI.
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Atherosclerotic coronary artery disease (CAD) and myo-
cardial infarction (MI) are complex traits that account for
the leading cause of death in the Western world, heart
disease, projected by 2020 to be the number one cause of
death and disability worldwide.1 Multiple previous studies
have documented the heritability of CAD and, in partic-
ular, its most acute manifestation, MI.2,3 Genomewide
linkage analysis is an unbiased approach that may lead to
the identification of previously unknown genetic loci or
genes for CAD and MI. Genomewide linkage scans with
hundreds of sibling pairs have identified several major ge-
netic susceptibility loci for CAD or MI.2–4 The MI suscep-
tibility gene on chromosome 13q12 has been identified
as ALOX5AP (MIM 603700), encoding 5-lipoxygenase–
activating protein.5,6 For the chromosome 3q CAD locus,
two candidate genes, GATA2 (MIM 137295) and Kalirin
(MIM 604605), were associated with CAD.7,8 The genes at
other loci have not yet been reported.
This study focuses on a susceptibility locus for MI on
chromosome 1p34-36, reported by us.9 We studied 428
multiplex families (GeneQuest) with at least two sibs af-
fected with premature CAD in each family and with one
nonaffected sib in a majority of the families. Genomewide
linkage analysis with the GeneQuest cohort identified a
genetic susceptibility locus for premature MI on chro-
mosome 1p34-36 in the American white population.9
Here, we report the results from the analysis of potential
candidates for MI at the 1p34-36 locus. The LRP8 gene
(MIM 602600) showed significant association with CAD
and MI in three independent populations affected with
familial CAD and MI: the GeneQuest and GeneQuest II
populations, which are two family-based American co-
horts with early-onset disease, and an Italian cohort. The
LRP8 protein is also known as the “apolipoprotein E re-
ceptor 2.” It is a lipoprotein receptor from the low-density
lipoprotein (LDL) receptor family.10 The structure of LRP8
closely resembles the LDL receptor and the very-low-
density lipoprotein receptor (VLDLR). The LRP8 gene is
highly expressed in the brain and testes, but it is also
expressed in the heart, endothelial cells, vascular smooth
muscle cells, and platelets.11 Binding of LDL to LRP8 ac-
tivates the phosphorylation of LRP8, which further acti-
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No. of males; females 248; 133a 121; 62a 1,010; 221a 269; 291 199; 49a 214; 94
Age (years) 40.2  4.9a 39.6  5.1a 60.6  12.1a 53.5  12.1 60.9  9.6b 58.1  12.6
Ethnicity White White White White Italian Italian
Family history of disease Yes Yes Sporadic NA Yes NA
Smoking (%) 79.0a 86.3a 75.4a 47.2 70.0a 45.1
BMId 29.6  5.6 28.9  6.3 29.7  8.2 29.2  7.1 26.4  3.3c 25.3  3.3
Hypertension (%) 47.9 43.7 71.9a 43.4 65.3a 33.1
Diabetes (%) 16.5a 12.0 30.6a 7.9 23.4a 13.5
Total cholesterol (mg/dL) 219.2  57.0a 205.2  58.2a 172.9  44.2a 188.2  43.2 221.9  45.9a 213.4  45.5
HDL cholesterol (mg/dL) 39.0  11.2a 37.2  13.5a 41.1  11.3a 45.1  14.6 NA NA
LDL cholesterol (mg/dL) 135.1  43.2a 122.7  50.5a 96.9  35.1a 116.6  35.9 151.5  38.4a 138.7  36.8
Triglycerides (mg/dL) 239.4  24.6a 222.0  20.5a 180.5  26.2a 135.0  82.5 178.0  79.9a 136.5  52.0
NOTE.—Data are shown as mean  SD, unless otherwise indicated. Age p age at onset for cases and age at examination for controls; HDL p
high-density lipoprotein; NA p not applicable.
a , compared with controls.P ! .001
b , compared with controls.P ! .01
c , compared with controls.P ! .05
d BMI measured as body weight in kilograms divided by the square of height in meters.
vates the p38 mitogen-activated protein kinase (MAPK)
stress-response signaling pathway, leading to platelet ag-
gregation and, potentially, thrombosis and MI.12 Func-
tional studies revealed that the nonsynonymous SNP
R952Q of LRP8, which was associated with CAD and MI,
significantly increased the activation (phosphorylation)of
p38 MAPK by LRP8 after treatment with oxidized LDL.
Our results suggest that LRP8 is a novel susceptibility
gene for familial and premature CAD and MI.
Material and Methods
Study Populations
The GeneQuest population consists of 1,613 individuals from 428
multiplex families with premature CAD and MI.9 Each family has
at least two affected sibs. The details, including diagnostic criteria
for CAD and MI, have been described elsewhere.9 For the case-
control association study, the probands from the GeneQuest fam-
ilies were grouped together as the case group. Only 381 white
patients with available DNA samples were selected, among which
183 were patients with MI. Patients of other ethnic origins were
excluded, to avoid the confounding effects of population admix-
ture. The 560 controls were selected from 19,800 individuals who
underwent coronary angiography in Cardiac Catheterization Lab-
oratories at Cleveland Clinic (Cleveland GeneBank), and only
white individuals without atherosclerotic lesions detectable by
angiography were included. A total of 1,231 patients with MI were
selected from GeneBank and were used as a replication cohort.
The second familial and premature CAD- and/or MI-affected
population, GeneQuest II, was ascertained using criteria9 identical
to those that defined the original GeneQuest population at the
Center for Cardiovascular Genetics of the Cleveland Clinic. A
total of 22 white families with 441 family members were enrolled.
The average size of the GeneQuest II families is 20 14 members,
and the number of affected individuals is 140.
The Italian cohort was enrolled in Verona, Italy, and details
about this study population were described elsewhere.13 The co-
hort consisted of 416 unrelated individuals with MI (248 with
family history), and 308 controls with no detectable stenosis by
coronary angiography.
This study was approved by local institutional review boards
on human subjects, and informed consent was obtained from the
participants. Whole blood was drawn from each participant, and
genomic DNA was isolated from the blood by use of standard
protocols.
Genotyping of SNPs
High-throughput SNP genotyping was performed using the 5′ nu-
clease allelic discrimination assay (TaqMan Assay) on an ABI
PRISM 7900HT Sequence Detection System. The assay includes
the forward target-specific PCR primer, the reverse primer, and
the TaqMan MGB probes labeled with two special dyes: FAM and
VIC. The probes were purchased through TaqMan Assays-on-
Demand or Assays-by-Design from Applied Biosystems (ABI). Ge-
notyping was performed in a total 5-ml PCR volume containing
2.5 ml of TaqMan Universal PCR Master Mix, 0.25 ml of 20#
TaqMan MGB Assay Mix, and 25 ng of genomic DNA. Automatic
allele calling was performed by ABI PRISM 7900HT data collection
and analysis software, version 2.1.
Direct DNA sequence analysis of SNPs in 24 DNA samples was
used to ensure the quality of SNP genotyping. Direct DNA se-
quence analysis was performed using an ABI PRISM 3100 Genetic
Analyzer. A DNA fragment containing the SNP was PCR amplified
in a 25-ml volume containing 2.5 ml of 10# PCR buffer (1.5 mM
MgCl2, 2.5 ml of 0.2 mM deoxynucleotide triphosphates, 0.5 mM
of each PCR primer, 1 U of Taq polymerase, and 50 ng of genomic
DNA). PCR products were separated from agarose gels, were iso-
lated and purified using the QIAquick PCR Purification Kit (QIA-
GEN), and were sequenced with both forward and/or reverse
primers. The sequencing reaction was performed using the
BigDye Terminator v1.1 Cycle Sequencing Kit (ABI).
Activation Assay of p38 MAPK
The green fluorescent protein (GFP)–tagged human LRP8 gene
was PCR amplified with primers containing inframe HindIII and
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Table 2. Analysis of Candidate Genes
at the 1p34-36 MI Locus for Association






MFAP2 17.1 rs2235932 .552 .632
PLA2G2A 20.1 rs4744 .202 .476
HMGCL 23.9 rs719400 .375 .338
LDLRAP1 25.6 rs11563 .686 .246
NR0B2 26.9 rs7504 .131 .288
SLC9A1 27.2 rs11247613 .683 .852
AK2 33.1 rs998664 .197 .300
GJB5 34.9 rs2275229 .730 .700
CSF3R 36.6 rs3917924 .630 .500
CDC20 43.5 rs839763 .815 .744
FAAH 46.6 rs324420 .916 .736
LRP8 53.5 rs5174 .003 .004
NOTE.—The entire 1p34-36 locus spans a region
from 4.0 Mb (CATC015) to 59.1 Mb (GATA26G09P),
with the plateau of genomewide significance from 13.2
Mb (GATA27E01) to 34.1 Mb (ATA79C10) (information
on the markers can be found at Marshfield Genotyping
Service).
a Positions as shown in the UCSC Genome Browser.
b P value for association with CAD.
c P value for association with MI.
BamHI restriction sites. The PCR fragment was digested with
HindIII and BamHI and was subcloned into the pEGFP C1 vector
cut with the same enzymes. Mutant LRP8 containing the SNP
R952Q was generated by PCR-based site-directed mutagenesis, as
described elsewhere.14 Both the wild-type and mutant LRP8 ex-
pression constructs were verified by direct DNA sequence analysis
of the entire inserts.
Meg-01 cells (American Type Culture Collection) were grown
in the RPMI-1640 medium containing 10% fetal bovine serum
and were maintained at a density of cells/ml. In general,53# 10
cells were used for experiments after 5 d of supplementation.
Transfection of Meg-01 cells was performed with 1 mg plasmid
DNA/well with a Nucleofector device and corresponding kits
(Amaxa) in 6-well plates. At 48 h after transfection, cells were
divided equally into five wells and were incubated with oxidized
LDL15 for 0, 20, 40, 60, and 120 min. Cells were lysed, and an
equal amount of total cellular proteins per sample was separated
with 12% SDS-PAGE gels and was electrotransferred onto poly-
vinylidene fluoride membranes. The blots were blocked in 5%
nonfat milk powder in phosphate-buffered saline Tween-20
(PBST) for 1 h, were washed briefly in Tris-buffered saline Tween-
20, and then were incubated with a primary monoclonal anti-
body directed against phosphor-p38 MAPK (D-8, catalog number
SC-7973 [Santa Cruz Biotechnology]) or a polyclonal antibody
against total p38 MAPK (C-20, catalog number SC-535 [Santa Cruz
Biotechnology]) in 5% nonfat milk and PBST overnight. Mem-
branes were then extensively washed in PBST (eight times for 5
min) and were incubated with a 1:2,000 dilution of horseradish
peroxidase–conjugated anti-mouse IgM (Sigma) for 1 h at room
temperature. Membranes were again washed (three times for 5
min each) in FBST, and ECL western-blotting detection reagents
(Amersham Pharmacia Biotech) were used to visualize the protein
signal. A prestained low-molecular-mass protein ladder (Bio-Rad)
was run in adjacent lanes. The images from western blots were
scanned and quantified. Relative signal density of phosphoryl-
ated p38 MAPK versus total p38 MAPK was calculated.
Platelet Aggregation Assays
Platelet aggregation assays were performed within 3 h after blood
collection. Aggregation was measured using an impedance
method on a Chrono-log Whole Blood Impedance Aggregometer.
A sample of 500 ml of blood was mixed with 500 ml of saline, and
the change in the impedance of the sample was measured in the
presence of adenosine diphosphate (ADP) during a 6-min test run
and was recorded on a computer with the Chrono-log AGGRO/
LINK software. Impedance aggregation in ohms was used to index
the rate and the degree of platelet aggregation.
To avoid the confounding effects of antiplatelet medications,
we conducted statistical analysis of the data from the platelet
aggregation assay only for 56 well-characterized patients with MI
who were verified as having no history of taking antiplatelet drugs
(e.g., aspirin). To reveal the relationship between platelet aggre-
gation and LRP8 SNPs, an autosomal dominant model (i.e.,
) was evaluated in the framework ofmean pmean (meanAA Aa aa
a general linear model (SAS, version 9.00).
Statistical Analysis
All SNPs were tested for Hardy-Weinberg equilibrium among con-
trols by use of the Haploview software package, version 3.0. All
SNPs were in Hardy-Weinberg equilibrium ( ).P 1 .05
Association of SNPs with the disease was assessed using Pear-
son’s contingency table x2 test or Fisher’s exact test (SAS,2# 2
version 9.00). Odds ratios (ORs) and 95% CIs were estimated using
the x2 test (SAS, version 9.00). Multivariate analysis was per-
formed by incorporating age and sex as covariates by use of mul-
tivariate logistic regression or in combination with additional
covariates, including total cholesterol and triglyceride levels.
Smoking was not included in the analysis because of lack of de-
tailed phenotypic data. Genotyping data were analyzed addition-
ally for association with CAD or MI by use of the Z-score
method.16 Empirical P values were calculated using 10,000 Monte
Carlo simulations, by the CLUMP program17 (Software Written
by Dave Curtis Web site).
A sib–transmission/disequilibrium test (TDT) analysis was per-
formed using the TDT/S-TDT program 1.1.18–20 The sib-TDT was
performed for CAD only because the sample size for MI was small
for a sib-TDT analysis.
To remove the effects of the LRP8 genetic variant encoding
R952Q from the original 1p34-36 linkage signal, we used multiple
regression models with the LRP8 SNP identical by descent (IBD)
considered as a covariate, to demonstrate its influence on the
original linkage profile. In detail, the new Haseman-Elston re-
gression uses the following form of a general linear model:
ˆ ˆˆ ˆyp a a p  d f  a p  d f  c f(z )  ,m m m 2m s s s 2s k k
where y is the quadratic form of the phenotypes of the siblings
(here, the mean-corrected trait cross-product); a is the intercept;
the subscripts m, s, and k represent the original microsatellite
marker, the LRP SNP, and the covariate sex, respectively; d is the
dominant genetic variance due to the marker or the SNP; a is the
additive genetic variance due to the marker or the SNP; ck is a
nuisance parameter accounting for the effect of mean-corrected
cross-product of sex ( ); and is the residual error. and ˆˆf(z )  p fk 2
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Risk Minor HWb Observedc Adjustedd Empiricale
GeneQuest CAD and control A A 381 (44.9) 560 (37.8) 1.35 .28 .003 .009 .003
GeneQuest MI and control A A 183 (46.2) 560 (37.8) 1.42 .28 .004 .010 .004
Italian MI and control A A 248 (40.6) 308 (33.6) 1.35 .34 .016 .020 .019
Combinedf A A 651 (42.9) 868 (36.3) 1.31 .36 .0004 .0003 .0006
a Allele A at the nucleotide level corresponds to variant 952Q at the protein level.
b P value for Hardy-Weinberg disequilibrium analysis.
c Uncorrected P value.
d P value obtained after adjustment for sex and age. Multivariate analysis was also performed for plasma total cholesterol levels, triglyceride
levels, hypertension, and diabetes in addition to age and sex for GeneQuest CAD ( ), GeneQuest MI ( ), Italian MI ( ), andPp .006 Pp .003 Pp .041
combined ( ) populations.Pp .0005
e Permutation P value calculated using 10,000 Monte Carlo simulations.
f Combined population comprised 381 CAD cases from GeneQuest population, 22 MI probands from GeneQuest II population, and 248 Italian
cases from familial MI population.
Table 4. Comparison of Two Different
Statistics in Analyzing the Association








x2: 9.05 8.16 6.95
P .003 .004 .008
Z score: 3.00 2.82 2.66
P .003 .005 .008
are the probabilities of mean IBD sharing and exactly 2 alleles
IBD sharing, respectively. Note that S.A.G.E. 5.3 reports only 8
decimal places, instead of 12 decimal places as in the previous
version used to analyze the original GeneQuest pedigrees.21
Results
Risk of CAD and MI Conferred by LRP8 SNP R952Q
in the GeneQuest Population
Initially, we employed a population-based case-control as-
sociation study design to characterize the candidate genes
for MI at the 1p34-36 locus. The 381 CAD cases were the
white probands, one per family, from the GeneQuest fam-
ilies with familial premature CAD and MI.9 Among them,
183 had well-characterized MI and served as the MI cases.
We excluded individuals of other ethnic origins, to min-
imize the confounding effects of population admixture.
The 560 controls were independent white individuals who
were enrolled at Cleveland Clinic and showed no detect-
able stenosis by coronary angiography. The clinical fea-
tures of cases and controls are shown in table 1.
We employed a type of systematic approach to analyze
candidate genes across the entire 1p34-36 region (4.0–59.1
Mb) on the basis of a gene’s position and function. For
the genetic interval under the linkage peak (13.2–34.1
Mb), one gene every 1–3 Mb was selected. For the genetic
intervals outside the linkage peak (4.0–13.2 and 34.1–59.1
Mb), one gene every 3–6 Mb was selected. Genes with
physiological functions relevant to those involved in the
development of CAD or MI were prioritized. Twelve can-
didate genes were identified for analysis in this manner
(table 2). One SNP was studied for each gene, on the basis
of its availability in the ABI Assays-on-Demand, minor-
allele frequency (MAF) 130% (on the basis of the assump-
tion that common disease may be associated with evo-
lutionarily old, common variants), exonic position, and
nonsynonymous nature, if possible. Of the 12 genes
tested, only a single SNP, a nonsynonymous variant lo-
cated within the LRP8 gene (rs5174 [R952Q]; dbSNP da-
tabase), showed significant association with CAD and MI
( for CAD and for MI; for CADPp .003 Pp .004 Pp .036
and for MI after adjustment by approximate Bon-Pp .048
ferroni correction22) (table 2).
Permutation testing also showed a significant empirical
P value for the association between SNP R952Q and CAD
(empirical ) or MI (empirical ) (table 3).Pp .003 Pp .004
Multivariate analysis was performed to examine the pos-
sible confounding effects of age, sex, and other factors,
and we found that SNP R952Q can be considered an in-
dependent risk factor for CAD ( after adjustmentPp .009
for age and sex; after adjustment for age, sex,Pp .006
total cholesterol levels, triglyceride levels, hypertension,
and diabetes) and MI (adjusted P values of .010 and .003,
respectively) (table 3). We also used the Z-score method16
to analyze the SNP data; by this method, the R952Q var-
iant was significantly associated with CAD and MI (table
4). These results suggest that LRP8 SNP R952Q is associ-
ated with premature CAD and MI in an American white
population.
To determine whether the SNP in LRP8 that was asso-
ciated with CAD and MI is relevant to the previous 1p34-
36 MI linkage, we investigated the covariate effects of the
LRP8 SNP on the original chromosome 1 linkage profile.
SNP R952Q appeared to explain a significant amount of
the original linkage signals (particularly the additive com-
ponent) (fig. 1).
Variant Associated with Risk of CAD and MI in the LRP8
Section of Haplotype Block LD5
The LRP8 gene contains 19 exons spanning ∼60 kb. SNP
R952Q, showing positive association in the above-
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Figure 1. Relationship between LRP8 SNP R952Q and the chromosome 1p34-36 premature MI susceptibility locus. The X-axis shows
the position of markers, and the Y-axis is log(P).
described study, is located in exon 19. Analysis of the
HapMap data showed that LRP8 is composed of five link-
age disequilibrium (LD) blocks (LD1–LD5, from the 5′ end
to the 3′ end of the gene) among individuals of European
American ancestry. SNP R952Q is in LD5 at the 3′ terminus
of the LRP8 gene. To test the association of other LD blocks
of LRP8 with CAD and MI, one SNP was selected from
each block on the basis of the criteria described above
(rs3820198 in LD1, rs1288480 in LD2, rs867884 in LD3,
and rs12039021 in LD4) and was used for fine-scale as-
sociation mapping in LRP8. No association was detected
between these SNPs and CAD or MI ( ) (tablePp .16–.94
5). These data suggest that only LD5, the most 3′ block of
LRP8, is associated with risk of CAD and MI.
Further analysis of SNP genotyping data from the
HapMap data revealed that LD5 of LRP8 extends beyond
the 3′ end of the LRP8 gene and spans additional genes,
MAGOH and FLJ20580. MAGOH, encoding a component
of the multiprotein exon-junction complex, resides at 14.6
kb from the 3′ end of LRP8. Tag SNPs capturing MAGOH
(rs6673692 and rs10788949) were selected and tested, but
we did not find any association with CAD ( andPp .61
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Table 5. Analysis of Association between SNPs in Blocks





OR (95% CI) PCases Controls
With CADa:
rs3820198 34.7 36.5 .92 (.75–1.13) .439
rs1288480 34.3 33.6 1.03 (.84–1.27) .761
rs867884 40.3 37.9 1.09 (.90–1.35) .327
rs12039021 41.8 41.6 1.01 (.83–1.23) .938
With MIb:
rs3820198 34.2 36.5 .90 (.69–1.18) .454
rs1288480 36.4 33.6 1.13 (.86–1.48) .370
rs867884 42.4 38.0 1.20 (.93–1.56) .162
rs12039021 43.1 41.6 1.06 (.82–1.38) .631
a GeneQuest CAD population (381 cases) and 560 controls.
b GeneQuest MI population (183 cases) and 560 controls.
Table 6. Analysis of Association
between Two Additional Genes in






53,469,727 rs6673692 .608 .131
53,468,639 rs10788949 .945 .583
FLJ20580:
53,454,287 rs1134688 .926 .958
43,018,309 rs1056425 .743 .565
a Positions in bases as shown in the UCSC
Genome Browser.
b P value for association with CAD.
c P value for association with MI.
.95, respectively) or MI ( and .58, respectively)Pp .13
(table 6). Additionally, we tested two SNPs in FLJ20580
(rs1056425 and rs1134688), which is the gene distal to
MAGOH (30 kb from LRP8), but, again, we did not find
any association with CAD ( and .93, respectively)Pp .74
or MI ( and .96, respectively). These data suggestPp .57
that MAGOH and FLJ20580 are not associated with CAD
or MI and that functional variants conferring risk of CAD
and MI reside within LRP8.
Similar to the HapMap data, in the GeneQuest control
population, LRP8 SNP R952Q is in a continuous haplotype
block (LD5) with rs6673692 and rs10788949 in the
MAGOH gene and with rs1056425 and rs1134688 in the
FLJ20580 gene (fig. 2). However, in the CAD- and MI-
affected populations, LD5 was disrupted, and SNP R952Q
was cut off from the block (if LD significance is equal to
). These results suggest that disruption of an LD′D 1 .8
block in a disease population may be considered as sup-
portive evidence of its association with the disease.
Family-Based TDT
Sib-TDT was used to determine whether the risk allele of
a SNP was transmitted preferentially to affected offspring.
If a specific allele is transmitted more frequently to af-
fected offspring, the allele is both linked and associated
with CAD.20 Sib-TDT is also an effective strategy to min-
imize the confounding effects of population admixture.
LRP8 SNP R952Q was genotyped in the full GeneQuest
cohort (table 7), including probands and other family
members. Sib-TDT of the genotyping data revealed that
R952Q was significantly associated with CAD ( )Pp .005
(table 8). Together, these data suggest that SNP R952Q is
associated with CAD by use of both population- and
family-based study designs with the GeneQuest cohort.
Association of LRP8 SNP R952Q with CAD
in the GeneQuest II Families
Recently, we enrolled 441 individuals from 22 large white
families (GeneQuest II replication population, average
pedigree size of 20) (table 7), to test further the association
of LRP8 with CAD. Selection criteria for GeneQuest II were
identical to those for the original GeneQuest cohort.9
Briefly, each proband must have presented with “prema-
ture” CAD, which was defined as any previous or current
evidence of significant atherosclerotic CAD occurring in
males aged 45 years or females aged 50 years. For re-
cruitment, each proband was required to have at least one
other living sibling who met the same criteria. SNP R952Q
was genotyped in the GeneQuest II cohort. Sib-TDT of the
genotyping data showed that SNP R952Q was significantly
associated with CAD ( ) (table 8). These resultsPp .009
from the GeneQuest II families provide the first replication
of association between SNP R952Q and CAD in American
white families with premature CAD.
Validation of Association of LRP8 SNP R952Q with MI
in an Italian Cohort
To replicate further the association of LRP8 with MI, we
studied a separate white population from Italy with fa-
milial MI. Of a total of 416 MI cases, 248 (60%) were
individuals with a family history of MI and were selected
for further study. We genotyped SNP R952Q in the Italian
cohort (248 MI cases and 308 controls) (table 1). The SNP
showed significant association with MI (table 3) and was
further confirmed by permutation testing, yielding a sig-
nificant empirical P value. Significant association was also
identified when all 416 Italian MI cases were analyzed
together ( ). These results were also significant af-Pp .008
ter adjustment for age, sex, triglyceride levels, total cho-
lesterol levels, hypertension, and diabetes (table 3). These
results provide the second replication of our finding of
association between LRP8 SNP R952Q and CAD and MI.
Assessment of Association of LRP8 SNP R952Q with CAD
in a Combined White Cohort
To provide a comprehensive assessment of the association
of LRP8 SNP R952Q with CAD, we performed an analysis
of all familial white CAD populations combined (651 cases
and 868 controls), as suggested by Skol et al.16 The sig-
Figure 2. Pairwise LD analysis. LD between SNPs in LRP8, including R952Q (rs5174), and SNPs in two nearby genes (rs6673692 and
rs10788949 in MAGOH and rs1134688 and rs1056425 in FLJ20580) was derived from genotyping data from the GeneQuest control (top)
and MI (bottom) populations. LD for the CAD population was nearly identical to the MI population (data not shown). The pairwise
correlation between SNPs was measured as D′ and is shown (#100) in each diamond. The red-to-white color gradient indicates the
magnitude of pairwise LD, ranging from higher to lower values of LD.
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Table 7. Demographic Features of the GeneQuest and
GeneQuest II Family-Based Study Populations
Feature GeneQuest GeneQuest II
No. of individuals 1,769 441
No. of males; females 1,018; 751 216; 225
Ethnicity White White
Pedigree structure:
No. of pedigrees 378 22
No. of sibships 384 118
Pedigree size (mean  SD) 4.7 1.3 20.1 13.8
Sibship size (mean  SD) 2.6 1.2 2.6 1.9
No. affected with CAD/MI 757 140














GeneQuest A 170 2.63 .005
GeneQuest II A 72 2.34 .009
a Allele A at the nucleotide level corresponds to variant 952Q
at the protein level.
b The number of minor alleles among affected sibs across all
sibships.
nificant P values for association of CAD with the LRP8
SNP R952Q were improved by 110-fold ( –Pp .0003
.006). Multivariate analysis with age and sex as covariates
showed a significant P value of .0003. The P value re-
mained significant after the factors plasma total choles-
terol levels, triglyceride levels, hypertension, and diabetes,
in addition to age and sex, were included as covariates
( ) (table 3).Pp .0005
SNP R952Q and the Function of LRP8
LRP8 SNP R952Q is a nonsynonymous substitution of
a positively charged arginine residue by a negatively
charged glutamine residue. To clarify whether this SNP
can affect the function of the LRP8 protein, we transfected
mammalian expression constructs with either wild-type
LRP8 or mutant LRP8 with the variant encoding R952Q
into Meg-01 cells. Cells were treated with oxidized LDL
for various times, and activation of p38 MAPK was as-
sayed. Six replicate experiments showed that the peak
phosphorylation level of p38 MAPK by mutant LRP8
R952Q was greater than that by the wild type ( ),Pp .009
and the high level of phosphorylation of p38 MAPK was
maintained for a much longer time ( at 120 min)Pp .001
(fig. 3). These results suggest that the R952Q variant of
LRP8 is a functional SNP that results in increased phos-
phorylation (activation) of p38 MAPK.
We further studied the correlation of LRP8 SNP R952Q
with activity of platelet aggregation in 56 patients with
MI who did not take any antiplatelet medications. As
shown in figure 4, the R952Q variant was associated with
a small but significant increase (14%) of platelet activity
at two concentrations of the ADP agonist ( andPp .02
.03).
Lack of Association of LRP8 SNP R952Q with MI
in Sporadic Disease
Since we identified a consistent association of LRP8 SNP
R952Q with CAD and MI in three populations with fa-
milial and premature disease, we wanted to test whether
the association held in patients with sporadic and late-
onset disease. To this end, we studied one population with
primarily sporadic CAD and MI, the Cleveland GeneBank
cohort (table 1). It is interesting to note that one other
major difference in this population, compared with the
previous populations, is the markedly reduced total and
LDL cholesterol and triglyceride levels (table 1). We ge-
notyped the GeneBank cohort, consisting of 1,231 pa-
tients mostly with late-onset, sporadic MI, and compared
allelic frequencies with those for the 560 unaffected con-
trols. No significant association was identified (table 9).
These results suggest that the functional LRP8 SNP R952Q
may be associated with familial, premature CAD and MI
but not with the sporadic form of the disease.
Discussion
Here, we report the identification of association of a pre-
viously unknown susceptibility gene, LRP8, with familial
and premature CAD and MI. Several lines of evidence
strongly support this conclusion. (1) By use of a popula-
tion-based approach, SNP R952Q, residing in the last LD
block (LD5) at the 3′ terminus of LRP8, showed a signifi-
cantly increased risk of premature, familial CAD and MI
in an American white population (GeneQuest). (2) LRP8
SNPs in the other four LD blocks (LD1–LD4) showed neg-
ative association with CAD and MI. (3) SNPs in other can-
didate genes within the 1p34-36 linkage interval were not
associated with CAD and MI, including MFAP2, PLA2G2A,
HMGCL, LDLRAP1, NR0B2, SLC9A1, AK2, GJB5, CSF3R,
CDC20, FAAH, MAGOH, and FLJ20580. (4) Family-based
(TDT) analysis showed that the risk allele of SNP R952Q
was transmitted preferentially to affected individuals in
GeneQuest families and provided further support that the
LRP8 variant conferred risk of CAD. (5) Family-based
(TDT) analysis showed that SNP R952Q conferred risk of
CAD in another, independent population with familial
CAD, the GeneQuest II American white families with pre-
mature CAD. (6) Another replication was made in an Ital-
ian white population with familial MI by use of a pop-
ulation-based approach. (7) Further analysis with all
familial combined populations with CAD and/or MI
showed highly significant association between LRP8 SNP
R952Q and CAD and MI (empirical ). (8) Func-Pp .0006
tional studies demonstrated that SNP R952Q has a pro-
nounced effect on the function of LRP8. Together, these
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Figure 3. Effects of the LRP8 R952Q SNP on phosphorylation of p38 MAPK induced by oxidized LDL (ox-LDL). Meg-01 cells were
transfected with pEGFP-hLRP8 wild type (WT) or pEGFP-hLRP8 mutant (R952Q) by use of Nucleofector. After 48 h, cells were incubated
with ox-LDL (2 mg/ml) for different times and were lysed. An equal amount of total cellular proteins (30 mg) was analyzed for
phosphorylated (p-p38) and total p38 MAPK by western-blot analysis. A representative image of the blot is shown (A). The images
were scanned and quantified. The experiments were replicated six times, and the graph (B) represents the data from six independent
experiments. Data are shown as mean  SD densitometric units.
results suggest that LRP8 SNP R952Q conferred risk of fa-
milial and premature CAD and MI.
Platelets are a critical component of the atherosclerotic
process.23 Platelets are known to secrete and express sub-
stances for coagulation and inflammation that may play
roles in atherosclerosis.23 The activation of platelets is a
key risk factor for atherothrombosis. Interestingly, we
found that the LRP8 SNP R952Q, associated with CAD and
MI, was also associated with a modest but significant in-
crease in platelet aggregation activity in 56 patients with
MI who had not received antiplatelet therapy. Thus, one
mechanism by which the LRP8 variant increases risk of
CAD and MI may be through sensitization of platelets.
LRP8 has been shown to be a receptor for LDL and acts
by homodimerization or heterodimerization with other
receptors (VLDLR and b2-glycoprotein I).12,24,25 LDL can
bind to LRP8, and the interaction induces tyrosine phos-
phorylation of LRP8 and activation of p38 MAPK in plate-
lets.12 LRP8 SNP R952Q increased the activation of p38
MAPK (fig. 3). Activation of p38 MAPK may influence the
sensitization of platelets by LDL, resulting in the forma-
tion of arachidonate metabolites and the release of in-
flammatory molecules, which may increase the risk of
atherosclerosis or atherothrombosis. The p38 MAPK is a
stress-activated protein kinase that may play a role in the
development of atherosclerosis. The p38 MAPK could af-
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Figure 4. Effects of LRP8 SNP R952Q on platelet aggregation
Table 9. Lack of Association of LRP8 SNP R952Q with
Sporadic CAD and MI in the GeneBank Population (1,231






Cases Controls Observedb Adjustedc
R952Q A 39.1 37.8 1.06 (.82–1.09) .439 .253
a Allele A at the nucleotide level corresponds to variant 952Q at the
protein level.
b Uncorrected P value.
c P value obtained after adjustment for sex and age.
fect leukocyte emigration and lead to increased leukocyte
accumulation in ischemic-reperfused tissue.26 The impor-
tant role of p38 MAPK in inflammation has been well
established, and overexpression of p38 MAPK has been
shown to induce myocardial fibrosis and inflamma-
tion.27,28 Kumar et al.29 showed that the activation of p38
MAPK was responsible for endothelial cell apoptosis in-
duced by g-irradiation. It has also been shown that p38
MAPK becomes activated during ischemia, and this acti-
vation leads to myocyte death and myocardial injury.30
SB203580, an inhibitor of p38 MAPK catalytic site, inhib-
ited ischemia-induced phosphorylation of p38 MAPK and
reduced myocardial infarction volume in mice.30 These
reported results are consistent with our finding that the
risk allele of SNP R952Q increased activation of p38 MAPK
and susceptibility to CAD and MI. Furthermore, the po-
tential roles of the LRP8 SNP in the pathogenic processes
of CAD and MI may go beyond the p38 MAPK activation
and platelet aggregation and may involve endothelial
cells, vascular smooth-muscle cells, and cardiac cells where
LRP8 is expressed. In addition, LRP8 is a receptor for apo-
lipoprotein E (apoE) and can bind and internalize apoE-
containing lipid vesicles. Mice deficient in apoE develop
atherosclerotic lesions, and depressed expression of apoE
has been associated with atherosclerosis in humans.31 Fu-
ture studies will define more precisely the mechanism by
which LRP8 variants play a role in the pathogenesis of
CAD and MI.
To the best of our knowledge, this study is the first to
employ the family-based SNP association design to iden-
tify a susceptibility gene for CAD and MI. Functional LRP8
SNP R952Q demonstrated significant association with
CAD and MI in two independent populations: GeneQuest
( ) and GeneQuest II ( ) (tables 7 and 8).Pp .005 Pp .009
Interestingly, the SNP R952Q was not associated with spo-
radic CAD and MI. This result likely reflects the sporadic
nature of MI in patients (mostly with no family history
of disease) in the Cleveland GeneBank cohort, in contrast
to CAD and MI in patients from the GeneQuest and
GeneQuest II families and the Italian cohort, with their
unique enrollment characteristics, such as early onset of
the disease (premature MI) and/or a family history of dis-
ease. These results further stress the importance of using
homogeneous populations, such as the GeneQuest,
GeneQuest II, and Italian cohorts, to identify the most-
reliable associations with MI with use of a case-control
design. Furthermore, unlike the Italian cohort, which was
enrolled on the basis of MI, the patients in GeneBank were
participants in a large 10,000-patient cardiovascular DNA
repository. Accordingly, the criteria for enrollment of a
population may also be important. Overall, these results
suggest that LRP8 is associated with early-onset and fa-
milial CAD and MI but not with late-onset, sporadic CAD
and MI. These results also suggest that familial and pre-
mature CAD and MI may be distinctively different genet-
ically from the late-onset, sporadic form of the disease.
It is important to point out that, as in other studies of
common complex diseases or traits, we cannot exclude
the possibilities that (1) other SNPs in LRP8 may be in LD
with SNP R952Q and also associated with CAD and MI or
that (2) LRP8 SNP R952Q may be in LD with variants in
additional genes in the 1p34-36 linkage interval that also
confer risk of CAD and MI. Such a case was reported for
the 3q CAD linkage, in which two candidate genes, GATA2
and Kalirin, were both associated with CAD.7,8,32 Never-
theless, our studies identified LRP8 SNP R952Q as a genetic
marker for association with premature, familial CAD and
MI. Future studies employing a systematic approach to
analyze each candidate gene under the 1p34-36 linkage
interval may identify other susceptibility genes for CAD
and MI.
In conclusion, we have demonstrated that the LRP8 SNP
R952Q is significantly associated with familial and pre-
mature CAD and MI but not with the sporadic and late-
onset form of the disease. Our results implicate a new,
LRP8-mediated molecular pathway for susceptibility to fa-
milial CAD and MI.
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